

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas Spies
Veronika Spies

Serial No.: 10/648,978

Filed: August 27, 2003

For: ACTIVATION OF LYMPHOCYTE
POPULATIONS EXPRESSING NKG2D
USING ANTI-NKG2D ANTIBODIES
AND LIGAND DERIVATIVES

Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: FHCC:010US

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This paper is submitted in response to the Restriction Requirement dated March 30, 2006, for which the date for response is May 1, 2006 (April 30th being a Sunday).

No fees are believed due; however, should any fees be due, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/FHCC:010US/SLH.

In response to the restriction requirement which the examiner imposed, Applicants elect, without traverse, to prosecute claims 1-3 and 5-13, *i.e.*, the Group II claims.

The examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,

/Steven L. Highlander/

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 28, 2006